The researchers have discovered that people who use weight loss have cast a much lower pounds in the real world compared to clinical trials.
JABS Like Wegovy and Mounjaro, which contains Smaglutide and Tirzepatide, respectively, She turned treatment From obesity, with Studies indicate Previous people can help lose up to 20 % of body weight after 72 weeks of treatment.
However, a new study indicates that medications, known as GLP-1 RAS, may not produce this sharp loss of weight in daily environments.
“The ordinary patient is on [GLP-1 RAs] Dr. Karan Xabra, author of the study, Dr. Karan Chapra, of the College of Medicine in Grossman at New York University, in the real world, does not get the weight loss that we see in clinical trials.
The researchers analyzed data from 51,085 patients with a 35 or more body mass index who were eligible for weight loss surgery and weight loss strikes.
The team compared weight loss in 38,545 people described from dolotid or Tirzepatide by their doctor, however in 12540 patients who underwent a weight loss surgery, over a period of up to three years.
After taking into account factors such as age, body mass index and health problems for the participants, the team found the patients who underwent surgery to treat obesity.
For example, two years later, people who underwent surgery to treat obesity have had a 26.5 % decrease in body weight, compared to 5.7 % for those identified GLP-1 RAS for any period.
The study has not been reviewed yet, and it is scheduled to be presented at the American Association for metabolism and obesity surgery 2025.
“The most reliable way to lose 20 % to 30 % of your weight is to get an obesity process,” said Chapra.
He said it was not clear why weight loss flips had a smaller influence in the real world compared to experiments, but he pointed out that its cost and other barriers that prevent access may mean that people are unable to continue their long -term use, while the efforts of doctors can also play a role, since it is important that the dose increases over time, the increase in support and additional support is monitored.
Chapra said more work is needed to ensure that patients who want to take such medications get the most effective.
“Our goal is to get the largest number of people to the correct treatment [for obesity] As much as possible. But they need to know what can be expected from the treatment they choose, and they should be guided by the real world data, not the clinical experience data. “
Professor Nid Saturn, from the University of Glasgow, who did not participate in the work, pointed to recent follow -up studies on Experiments involved Terzopatid Weight loss appears significantly over three years. But he said in real life, many patients stopped early because of their cost or side effects that are being dealt with poorly.
He said: “This has been said, the well -performed obesity surgery can work well for many people and certainly cheaper during the longest term.” “The problem may be that most people prefer to take weight loss medications rather than surgery, at least in the first place, and now that the drugs can deal with weight loss levels with surgery.”
